In cancer patients, PET imaging using radiolabeled PARP inhibitors has been demonstrated to highlight PARP-expressing head-and-neck tumors (20), breast cancer (16,33), and ovarian cancer (34) and to predict the efficacy of PARP inhibitor treatment (35). The gene discussed is PARP1; the disease is breast carcinoma.